[Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005382
German
Original Title:
Anwendungsbegleitende Datenerhebung zu Brexucabtagen Autoleucel: Prüfung des Studienprotokolls (Version 3.0) und des statistischen Analyseplans (Version 3.0) - 4. Addendum zum Projekt A21-130
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-89.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-89_brexucabtagen-autoleucel_addendum-zum-projekt-a21-130_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Mantle-Cell
- Antigens, CD19
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Antineoplastic Agents, Immunological
- Registries
- Product Surveillance, Postmarketing
Keywords
- Brexucabtagene Autoleucel
- Lymphoma – Mantle Cell
- Registries
- Benefit Assessment
- Research Design
- Peer Review – Research
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.